Study of BHV-1400 for IgA Nephropathy
This study is testing a treatment called BHV-1400 for people with IgA Nephropathy (IgAN), a kidney disease. The main goal is to see if BHV-1400 is safe and tolerable. Researchers will look at serious side effects, side effects that cause people to stop the study, and any deaths over a period of up to one year. They will also check for severe changes in lab test results. You can join if you are between 18 and 65 years old and have IgAN confirmed by a kidney biopsy. The study is currently unclear on its recruitment status and plans to enroll 20 participants.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 20 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to one year to monitor for side effects and lab abnormalities.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Study of BHV-1400 in IgA Nephropathy
At a glance
Conditions
Where it's being run
15 sites across 11 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of participants with Serious AEs (SAEs), AEs leading to discontinuation, deathsUp to 1 year
To assess the safety and tolerability of BHV-1400. This objective will be measured by assessing the number of unique subjects with SAEs, moderate or severe AEs, AEs leading to discontinuation or deaths
- Number of participants with Grade 3-4 treatment-emergent laboratory abnormalitiesUp to 1 year
To assess the safety and tolerability of BHV-1400. This objective will be measured by assessing the number of unique subjects with Grade 3 or 4 treatment-emergent laboratory abnormalities.